Alimera Sciences Inc. (NASDAQ: ALIM)
$5.57
-0.0300 ( -0.54% ) 125.4K
Alimera Sciences Inc is a commercial-stage pharmaceutical company developing and commercializing ILUVIEN for the treatment of diabetic macular edema (DME), a cause of blindness, and outside the U.S. for non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). ILUVIEN is a sustained-release intravitreal implant that enables patients to maintain vision longer, and importantly, with fewer injections. The company commercializes ILUVIEN in the U.S., Europe, China and the Middle East operations are managed as three operating segments: U.S., International and Operating Cost It generates maximum revenue from U.S. Segment.
Market Data
Open
$5.57
Previous close
$5.60
Volume
125.4K
Market cap
$291.28M
Day range
$5.53 - $5.63
52 week range
$2.61 - $5.65
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
4 | Insider transactions | 1 | Mar 13, 2024 |
10-k | Annual reports | 99 | Mar 08, 2024 |
8-k | 8K-related | 17 | Mar 07, 2024 |
8-k | 8K-related | 18 | Feb 09, 2024 |
4 | Insider transactions | 1 | Jan 11, 2024 |
4 | Insider transactions | 1 | Jan 04, 2024 |
3 | Insider transactions | 1 | Jan 04, 2024 |
8-k | 8K-related | 17 | Jan 04, 2024 |
3 | Insider transactions | 1 | Dec 13, 2023 |
4 | Insider transactions | 1 | Dec 13, 2023 |